(ALKS:Consolidated Issue Listed on NASDAQ Global Select )
Nancy J. Wysenski B.Sc., MBA
Director and Member of Nominating & Corporate Governance Committee, Alkermes plc
|Age||Total Calculated Compensation||This person is connected to 49 board members in 3 different organizations across 8 different industries.|
See Board Relationships
Ms. Nancy J. Wysenski, B.Sc., MBA served as the Chief Commercial Officer and Executive Vice President of Vertex Pharmaceuticals Incorporated from December 2009 to June 2012. Ms. Wysenski has broad responsibility for sales, marketing, market research and sales operations activities as the Vertex creates and executes commercial plans to support the potential launch of its late-stage product opportunities. She served as Chief Operating Officer of Endo Pharmaceuticals Solutions ...
Connaught HousePhone: 353 1 772 8000
Dublin, Co. Dublin 4
Board Members Memberships*
Former Director, Chairman of Compensation Committee, Member of Special Finance Committee and Member of Nominating & Corporate Governance Committee
Former Chief Operating Officer and Director
Director and Member of Nominating & Corporate Governance Committee
Independent Director and Member of Compensation Committee
Kent State University
Annual Compensation*There is no Annual Compensation data available.
Stock Options*There is no Stock Options data available.
|Jean-Jacques Bienaime MBA||Chief Executive Officer and Director|
BioMarin Pharmaceutical Inc.
|David M. Stack||Chairman, Chief Executive Officer and President|
Pacira Pharmaceuticals, Inc.
|Thomas W. D'Alonzo Esq., J.D.||Chairman, Acting Chief Executive Officer, Acting President, Member of Audit Committee, Member of Nominating/Corporate Governance Committee and Member of Compensation Committee|
Salix Pharmaceuticals Ltd.
|Vinita Gupta||Chief Executive Officer, Executive Director, Chief Executive Officer of Lupin Pharmacuticls Inc Usa and Group President of Lupin Pharmacuticls Inc Usa|
|Alessandro E. Della Chà LL.M||Chief Executive Officer and Director|
Cosmo Pharmaceuticals S.p.A.
|--||Compensation as of Fiscal Year 2013.|